|
|
|
| Effects of Sacubitril/Valsartan Sodium and Valsartan on Myocardial Enzymes, NT-proBNP and Inflammatory Factors in Elderly Patients with Coronary Heart Disease after PCI |
| ZHANG Zutao, LIAO Wei, ZHANG Nan, et al |
| Wuhan Asia Heart Hospital, Hubei Wuhan 430022, China |
|
|
|
|
Abstract Objective: To compare the effects of sacubitril/valsartan sodium and valsartan on myocardial enzymes, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and inflammatory factors in elderly patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods: The data of 139 elderly patients with coronary heart disease after PCI in our hospital from January 2020 to January 2022 were retrospectively collected, of which 40 patients received conventional western medicine treatment after PCI for coronary heart disease (control group), 50 treated with Shakubatrac valsartan sodium on the basis of routine treatment (Shakubatrac valsartan sodium group), and 49 treated with valsartan on the basis of routine treatment (valsartan group). The 3 groups were compared in terms of cardiac function, myocardial enzymes, NT-proBNP, and inflammatory factors. The incidence of major adverse cardiac events (MACE) was recorded. Results: The difference in left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) before and after treatment in the sakubactrovalsartan sodium group were higher than those in valsartan group and the control group (P<0.05). The difference between creatine kinase (CK), creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST), NT-proBNP, tumor necrosis factor (TNF)-α and interleukin (IL)-6 before and after treatment in sakubactrovalsartan sodium group were higher than those in valsartan group and the control group (P<0.05). The total incidence of MACE in the sakubactrovalsartan sodium group, valsartan group, and control group were 6.00%, 14.29% and 27.50%, the difference between the 3 groups was statistically significant (P<0.05). Conclusion: For elderly patients with coronary heart disease after PCI, sacubitril/valsartan sodium treatment can improve cardiac function, restore myocardial enzymes, lower the levels of NT-proBNP and inflammatory factors, and reduce the risk of MACE after the operation.
|
|
|
|
|
|
[1] 国家心血管病中心.中国心血管健康与疾病报告2020[J].心肺血管病杂志,2021,40(9):885-889.
[2] 代倩倩,石兆峰,胡嘉元,等.芪参益气滴丸联合西药治疗对经皮冠状动脉介入术后不良心血管事件及生活质量影响的Meta分析[J].中国中药杂志,2021,46(6):1498-1510.
[3] 夏勇,张建卿,王少霞,等.沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报,2020,41(1):113-118.
[4] Jackson AM,Jhund PS,Anand IS,et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J].Eur Heart,2021,42(36):3741-3752.
[5] Ou Y,Sun SJ,Shi HM,et alW.Protective effects of salvianolate on myocardial injury or myocardial infarction after elective percutaneous coronary intervention in NSTE-ACS patients:a randomized placebo-controlled trial[J].Chin Integr Med,2020,26(9):656-662.
[6] 秦少强,王亚玲,刘俊峰,等.芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心功能不全临床效果[J].中华中医药学刊,2020,38(4):201-203.
[7] Mann DL,Givertz MM,Vader JM,et al.Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction:a randomized clinical trial[J].JAMA Cardiol,2022,7(1):17-25.
[8] Wang HY,Xu B,Dou K,et al.Implications of periprocedural myocardial biomarker elevations and commonly used MI definitions after left main PCI[J].JACC Cardiovasc Interv,2021,14(15):1623-1634.
[9] Llacer P,Gallardo Ma,Palau P,et al.Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure[J].Med Clin (Barc),2021,156(12):589-594. |
|
|
|
2023, Vol. 29 
